Industry & RegulationMHRA Strategy 2030 promises 14-day reviews for first human trials
The UK regulator's five-year plan sets guaranteed assessment times backed by fee rebates, an AI protocol checker and a goal of third place globally for phase 1 trials.
14 October 2026